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Abstract
Background: Essential tremor (ET) is characterized by a frequent family history. No monogenic form of ET has been
identified. We aimed at exploring ET patients to identify distinct subgroups and facilitate the identification of ET
genes. We tested for the presence of HTRA2 p.G399S, and ANO3 p. W490C, p. R484 W and p. S685G mutations.
Methods: Between June 2011 and November 2013, all consecutive patients suspected with ET were prospectively
included in a prospective, monocentric study. Family history, age at onset (AAO), features of tremor, benefit of
alcohol and drugs, electrophysiological recording findings were collected. Sanger sequencing was performed for
HTRA2 and ANO3 mutations screening.
Results: Sixty eight patients were investigated. Fourteen diagnosed with psychogenic (5) or dystonic tremor (9)
were excluded. Regarding the 54 ET patients, mean AAO was 48 years (6–77), and mean disease duration 15 years
(1–55). Bimodal distribution of AAO was consistent with phenotypic subgroups. In patients with AAO before
30 years, marked benefit of alcohol (p < 0.01) and ET family history (p < 0.01) were more frequent and the disease
progression less severe (p < 0.0001). Neither HTRA2 nor ANO3 mutation were identified in our patients.
Conclusions: Our data support that distinct ET phenotypic subgroups may be encountered. We recommend to
study separately extreme phenotypes of ET, particularly autosomal dominant families with early AAO (<30 years)
and marked benefit of alcohol, to facilitate the identification of ET genes. Electromyographic recording remains a
support to distinguish ET from differential diagnosis. HTRA2 and ANO3 mutations are not common causes of ET.
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Background
According to the Consensus Statement of the Movement
Disorder Society (CSMDS) [1], essential tremor (ET) is
characterized by: (1) a bilateral, largely symmetric, pos-
tural tremor with or without kinetic component, which
affects hands and forearms, that is present for at least
5 years, visible and persistent, (2) additional or isolated
tremor of the head may occur but in the absence of
abnormal posturing, and (3) exclusion of other causes
for tremor (other neurological diseases, iatrogenic
tremor, exaggerated physiological tremor, recent history
of head trauma, psychogenic trigger). Nevertheless, de-
bates continue about the definition of ET because it is
an heterogeneous disorder that has no clear diagnostic
test [2].
Clinical practice emphasizes ET heterogeneity, and the
limits of the above definition: family history is frequent
but may be lacking, histogram of age at onset (AAO)
demonstrates bimodal distribution with a first peak in
childhood or adolescence [3] and a second around the
5th and 6th decades. In the same way, unilateral cases
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have been described [4], or cases associated with other
motor (rest tremor, cerebellar ataxia) or non-motor (de-
pressive syndrome, sleep disorders, cognitive decline)
signs have been reported [5], and response to alcohol or
to beta-blockers are only optional. Moreover, distinct
pathological patterns have been reported [6]: one with
cerebellar lesions, loss of Purkinje cells and presence of
torpedoes; another with brainstem Lewy bodies.
Such heterogeneity added to the lack of stringent
diagnostic criteria or of biomarkers and to the evidence
for non mendelian inheritance could explain the weak
profitability of genetic studies and their difficulty to
find reproducible data [7]. Indeed, a mutation in the
FUS gene [8] was found in only one ET family. LINGO1
and SLC1A2 polymorphisms have been only identified
in genome-wide association studies [9–11]. An HTRA2
variant has very recently been associated in one family
with ET and optional parkinsonism [12]. However, a clear,
monogenic form of ET is still lacking. ANO3 mutations
were reported in a spectrum of dystonic patients initially
presumed to have familial essential tremor [13].
We aimed at analysing a cohort of patients with ET to
identify distinct phenotypic subgroups in order to facilitate
the identification of genes responsible for ET, and searched
for HTRA2 and ANO3 mutations recently identified as
causes of family ET with extrapyramidal features.
Methods
From June 2011 to September 2013, all the patients re-
ferred in our tertiary movement disorders center with sus-
pected ET, according to the CSMDS [1] definition were
included in a prospective, monocentric study. All patients
provided informed consent for the study and to be video-
taped, and the local ethics committee approved the study.
Clinical examination
Following items were collected: family history, AAO,
current age, clinical features of tremor, severity scales
(The Essential Tremor Rating Assessment Scale score
(TETRAS) performance subscale [14]), marked benefit
of alcohol (patients were asked to answer to the question
“does your tremor markedly improve following alcohol
consumption”) and to drugs, clinical signs associated to
tremor, severity of disease progression (defined by the
TETRAS performance subscale/duration of ET ratio). A
video recording was performed for each patient, enab-
ling the confirmation of the diagnosis of ET by a second
neurologist devoted to movement disorders.
Electrophysiological recordings
Using (1) surface electrodes on extensor and flexor muscles
of both forearms, and on cervical muscles, and (2) an
unidirectional piezoelectric accelerometer placed on
the index finger of dominant hand, the following items
were analysed: the conditions of occurrence of the
tremor (rest, posture, intention), frequency, regularity,
agonist-antagonist synchronicity, distribution, and dis-
tractibility. Accelerometer signal was bandpass filtered
at 20–500 Hz. Postural and intention tremor were ana-
lyzed during postural maintenance and action (goal-di-
rected movements and drawing). The effect of mental
calculation was tested at rest. Patients with atypical
tremor including distractible electrophysiological pat-
terns (variations of frequency, transient disappearance
of the tremor) suggestive of psychogenic tremor and
patients with suspected dystonic tremor (abnormal pos-
ture, agonist-antagonist muscles co-contraction) were
excluded from the study.
Biology and Sanger sequencing
Cupper, ceruloplasmin and thyroid stimulating hormone
(TSH) serum levels were analysed in each patient. FMR1
premutation was investigated in all patients with onset
after 50 years in order to rule out fragile X-associated
tremor ataxia syndrome (FXTAS) [15]. For screening of
HTRA2 p.G399S, and ANO3 p.W490C, p.R484 W and
p.S685G variants recently reported as causes of ET,
DNA was extracted from whole blood using illustra™
DNA Extraction kit BACC3 (GE Healthcare UK).. The
coding exons of HTRA2 and ANO3, reported recently
[12, 13] were screened for mutations by Sanger sequen-
cing of genomic DNA. Fifty-microliter PCR reactions were
carried out with 40 ng of genomic DNA and 10pmol of
each pair of primer of forward and reverse primers using
KAPA Hifi Hotstart ReadyMix PCR Kit (KAPABiosystems,
Boston, Masschusetts, United States). Primer pairs are
available upon request. All PCR products were purified
and both strands were sequenced at GATC Biotech
(http//www.gatc-biotech.com/). Sequenced were analysed
using the SEQSCAPE v2.5 software (Applied Biosystems,
Courtaboeuf, France).
Brain MRI and DAT-SPECT
Cerebral MRI was performed in 28 cases and, dopamine
transporter single-photon emission tomography (DAT-
SPECT) was performed in 8 of the 10 patients who also
had rest tremor.
Statistical analysis
Statistical analyses were performed using parametric and
non-parametric tests, according to the data distributions.
Association between categorical variables was assessed
using Fisher-exact tests, because of the small popula-
tions in each level of the qualitative variables.
Correlation between quantitative variables has been
tested using Pearson correlation tests and Spearman cor-
relation tests, in order to check for linear and non-linear
correlation assumption.
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Link between a qualitative and a quantitative variable
was checked using the non-parametric Kruskal-Wallis
test, because of the nature of continuous variables distri-
butions. The Gaussian assumption of these formers was
not always checked (Shapiro-Wilk test), implying the use
of those non-parametric tests.
Alpha risk was fixed to 5%. Analyses were performed
using the R software (version 3.0.2).
Results
Sixty-eight patients were investigated. Taken together,
clinical and neurophysiological findings were finally con-
sistent with psychogenic tremor in 5 patients and dys-
tonic tremor in 9 patients who were excluded.
The main clinical and electrophysiological data of the
remaining 54 patients are summarized in Tables 1 and 2
and in Fig. 1.
Patients
The 54 studied patients had a mean age of 62 years
(range, 18 to 80) and had a mean history of tremor of
14.5 years (range, 1 to 55). The mean AAO was 48 years
(range, 6 to 77). Tremor age of onset showed a bimodal
distribution (Fig. 1). A positive family history of tremor
was present in 29 (54%) patients. The mean TETRAS
performance subscale was 8.5 (range, 1 to 21). Marked
benefit of alcohol was found in 13/44 (30%) patients.
Marked benefit of alcohol as well as positive family history
of ET were correlated with earlier age of onset (p = 0.008
and p = 0.0007, respectively). TETRAS score was higher
when head tremor was present (p < 0.001) but head
tremor was positively correlated with neither age of onset
nor tremor duration.
Tremor anatomic distribution and tremor patterns
All patients had bilateral upper extremities tremor, 4
(7%) an associated lower limbs and 14 (26%) an associ-
ated head tremor. Mean frequency of tremor was 6.3 Hz
(3.8–11) in upper extremities. All patients had postural
tremor, 46 patients (85%) an associated intentional tremor
and 10 (18%) an associated rest tremor.
Biological, brain MRI, DAT-SPECT and genetic data
Biological analysis (cupper, ceruloplasmin, TSH) was nor-
mal in all patients. All the 18 patients investigated for
FMR1 permutation were negative. No patients had HTRA2
p.G399S, or ANO3 p.W490C, p.R484 W and p.S685G
variant.
Brain MRI was normal in 13/28 cases, but demonstrated
vascular leucopathy in 9, cortical frontal atrophy in 2, inci-
dental meningioma in 2 (a parieto-occipital parasagittal
left meningomia (6 cm in diameter) and a frontal right
meningomia (2 cm in diameter)), and asymptomatic
aneurysm of a cerebral artery in 2 patients.
Table 1 Demographic, medical and upper limb
electrophysiologic data of the cohort




Mean age at evaluation, range 62 years (18–80)
Mean AAO of tremor, range 48 years (6–77)
Duration of tremor, range 14.5 years (1–55)
Family history of essential tremor 29 (54%)
Family history of Parkinson’s disease 2 (3.5%)
Family history of ataxia 0
Family history of other neurodegenerative disease 2 (3.5%)
Marked benefit of alcohol (n = 44 patients) 13 (30%)
Increased at morninga 10 (20%)
Increased with emotionsb 44 (82%)
Increased with physical exercisec 22 (41%)
Initial location of tremor
One hand 27 (50%)
Dominant hand 23 (42%)
Two hands 27 (50%)
Current location of tremor











TETRAS score (performance subscale), range 8.5 (1–21)
Electrophysiologic findings in upper limb extremities
Rest tremor 10 (18%)
Postural tremor 54 (100%)
Intentional tremor 46 (85%)
Postural tremor only 5 (9%)
Rest, postural and intentional tremor 8 (15%)
Frequency of postural tremor 6.3 Hz (3.8–11)
TETRAS The Essential Tremor Rating Assessment Scale; AAO age at onset,
Hz Hertz
aamplitude of tremor more important relative to the rest of the day
bamplitude of tremor more important with emotions (happiness, sadness)
camplitude of tremor more important with sustained exercise
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DAT-SPECT demonstrated the loss of dopaminergic
neurons in 4/8 patients with rest tremor.
Medications
Treatments and efficacy of treatments are summarized
in Table 3. None of the patients had received anti-
psychotic or anti-emetic drugs. None of the following
factors were found predictive of response to main anti-
tremor drugs (propranolol, primidone, topiramate): ET
family history (p = 0.28, p = 1.0, p = 1.0, respectively);
marked benefit of alcohol (p = 1.0, p = 1.0, p = 1.0, respect-
ively); associated rest tremor (p = 0.32, p = 1.0, p = 1.0, re-
spectively); symmetrical tremor (p = 0.62, p = 01.0, p = 1.0,
respectively); associated head tremor (p = 1.0, p = 1.0,
p = 1.0, respectively); associated lower limbs tremor
(p = 1.0, p = 0.30, p = 1.0, respectively); frequency (p = 0.67,
p = 0.73, p = 0.65, respectively); TETRAS performance
subscale (p = 0.97, p = 0.35, p = 0.65, respectively); evolu-
tion speed (ratio TETRAS performance subscale/duration
of tremor) (p = 0.92, p = 0.21, p = 0.65, respectively).
Discussion
We aimed at identifying extreme phenotype of ET that
could be distinguished from other ET variants in order
to find genes responsible for ET which appears to be
heterogeneous regarding both clinical and genetic basis.
Indeed, the identification of gene causing ET remains an
important genetic challenge in the field of movement
disorders.
Our study confirmed the bimodal distribution of AAO
and the frequent positive family history of ET [16, 17]
that support genetic heterogeneity of ET. In the same
way, our results further strengthen previous data showing
Table 2 Correlation between age at onset and other characteristics of tremor (n = 42 patients)
AAO≤ 30 years (early onset ET) AAO≥ 55 years (late onset ET) p
(n = 14) (n = 28)
Family history of essential tremor (n = 42) 93% (n = 13) 36% (n = 10) 0.0007
Benefit of alcohol (n = 33) 54% (n = 6) 9% (n = 2) 0.008
Duration of tremor, years (SD) (n = 42) 29 (+/−16) 6.5 (+/−6) <0.0001
TETRAS score/duration of tremor (SD) (n = 42) 0.4 (+/−0.2) 2.3 (+/−2.3) <0.0001
Head tremor (n = 42) 21% (n = 3) 29% (n = 8) 1.00
Lower limbs tremor (n = 42) 21% (n = 3) 0% (n = 0) 0.03
Rest tremor (n = 42) 21.4% (n = 3) 17.8% (n = 5) 0.85
Mean frequency, Hertz (SD) (n = 42) 7.0 (+/−2) 6.2 (+/−1) 0.23
TETRAS score (SD) (n = 42) 9.6 (+/−4) 7.8 (+/−5) 0.15
Response to beta-blockers (n = 23) 77% (n = 10) 70% (n = 7) 1.00
Response to primidone (n = 10) 80% (n = 4) 60% (n = 3) 1.00
AAO age at onset, SD standard deviation, TETRAS The Essential Tremor Rating Assessment Scale
Number of patients
Age at onset
Fig. 1 Bimodal distribution of age at onset of tremor
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that there is a correlation between a family history of
tremor and a younger AAO [18].
We found that early onset of tremor, marked benefit
of alcohol consumption and positive family history of
ET should be considered as such peculiar phenotype also
characterized by a less severe progression of the disease.
Thus, in order to identify genes causing ET, we recom-
mend to perform genetic analysis in patients with such
extreme phenotype. However, these new findings need
to be confirmed in larger series. Benefit of alcohol could
be quantitatively assessed [19] and could be underpinned
by a peculiar pathophysiological process. A family history
is clearly suggestive of inheritance of the disease and in
the same way, the youngest the onset, the most probable
the inheritance.
For the identification of such peculiar phenotype,
electrophysiological recording remains a strong support.
Indeed, we confirmed the difficulty in some patients to
distinguish ET from differential diagnosis such as dystonic
tremor or to some extent psychogenic tremor. Therefore,
we also recommend to perform electrophysiological re-
cordings for the selection of patients with genuine ET for
future genetic studies.
We found that tremor frequency and head tremor
should not be considered as determinant factors for the
identification of a peculiar phenotype. In our series,
some findings could be explained by the natural history
of ET rather than by different phenotypes of ET, since
patients with earlier age at onset had longer disease dur-
ation. Indeed, an age-associated decrease in tremor fre-
quency (approximately 0.06 to 0.08 Hz/year [20]) has
been confirmed in our series, where tremor frequency
was negatively correlated with current age (p < 0.01) and
TETRAS subscale performance (p < 0.01). Likewise, head
tremor which was present in only 11 patients (26.2%,
against 31 to 59.4% in previous series) [3, 21], was only
correlated with tremor severity (p < 0.001). In the same
way, the higher frequency of lower limb tremor in patients
with earlier age at onset could be due to the natural his-
tory of the disease rather than to a peculiar phenotype.
However, this statement remains to be confirmed by
further studies.
Rest tremor was present in 18% patients, but in oppos-
ite to previous data [22], no correlation was found with
neither tremor duration (p = 0.31) nor TETRAS subscale
performance (p = 0.2). Some authors suggested that in
patients with severe, old and disseminated ET, rest tremor
could be explained by diffusion of the pathologic process
to the dopaminergic system. However recent post-mortem
studies of a few ET patients with rest tremor did not re-
veal Lewy body pathology [6], and in our series, only four
from 8 patients with rest tremor and who underwent DAT
scan, demonstrated dopaminergic denervation.
Nevertheless, epidemiological studies have shown that
ET could be a risk factor for Parkinson’s disease (PD) [23].
Additional non motor signs such as anosmia or rapid eye
movement behaviour disorder in previous series [5] argue
for a link between PD and ET. Whether patients affected
with both ET and PD should be considered as suitable for
the identification of tremor-causing genes needs to be
confirmed in a near future. HTRA2 p.G399S variant has
recently been identified to be a risk factor with overlap-
ping family ET and PD but we did not find this variant in
our cohort [12]. In the same way, this variant has been
very recently searched for in a large series of ET and was
finally considered as not a common cause of ET [24, 25].
We did not find ANO3 mutations in any of our patient
using Sanger sequencing. These data have to be replicated
in a larger sample of ET patients.
Finally, our series confirmed the therapeutic efficacy of
propranolol and primidone [26], and to lesser extent of
topiramate, but did not identify any predictors of posi-
tive response for any of these drugs. Main limitation of
our study is the relatively small number of patients,
compared to previous series [3, 16, 21]. However its ori-
ginality consists of the theory of extreme phenotypes, of
comprehensive clinical and electrophysiological data,
and of up-to-date genetic studies.
Conclusions
Larger cohorts are probably needed to confirm that the
factors identified in the present study (early age of onset,
marked benefit of alcohol, dominantly inherited family
history of ET) correspond to an extreme phenotype of
ET. Our results suggest to study separately patients with
such peculiar phenotype in order to finally find gene re-
sponsible for ET.
Table 3 Treatments and efficacy of treatments
Medications Patients (n = 54 patients)
Propranolol (n = 31 patients)
Positive effect of propranolol 24 (77%)
Mean posology, en milligram/day, range 109 (40–300)
Mean length of treatment, months, range 57 (1–360)
Primidone (n = 16 patients)
Positive effect of primidone 13 (81%)
Mean posology, en milligram/day, range 338 (10–750)
Mean length of treatment, months, range 15 (1–60)
Topiramate (n = 7 patients)
Positive effect of topiramate 3 (43%)
Mean posology, en milligram/day, range 75 (25–150)
Mean length of treatment, months, range 11 (1–36)
Chronic high frequency thalamic stimulation 2 (4%)
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